[Form 4] VEEA INC. Insider Trading Activity
Rhea-AI Filing Summary
Mark Tubinis, Chief Commercial Officer of VEEA Inc. (VEEA), was granted options to purchase 125,000 shares of common stock on 09/29/2025 under the issuer's 2024 Incentive Equity Plan. The options have an exercise price of $0.66 and an expiration date of 09/29/2035. Initial vesting of 31,250 options (25%) occurs upon either shareholder approval for the grant or sufficient shares being available under the Plan and filing of a Form S-8, and only after the issuer recognizes $3 million in gross revenue. The remaining 93,750 options (75%) vest quarterly in equal installments over a three-year period following that initial vesting event. The filing lists Tubinis as the direct beneficial owner of 125,000 option-related shares and is signed by him on 10/02/2025.
Positive
- 125,000 option grant aligns executive incentives with company performance
- 25% of options vest upon achieving a clear $3 million gross revenue milestone
- Remaining 75% vests over three years, supporting retention
Negative
- Initial vesting depends on shareholder approval or filing a Form S-8, which may delay vesting
- No current share count or market price disclosed, so dilution impact is not quantifiable from this filing
Insights
Grant ties executive pay to a clear revenue milestone and administrative approvals.
The award links 25% of the option grant to the company achieving $3 million in gross revenue, which aligns part of the executive's upside with a concrete business outcome. The remaining 75% vests over three years, encouraging retention.
The initial vesting is also contingent on either shareholder approval or filing a Form S-8, creating an administrative dependency that could delay realization of the economic incentive until compliance steps are completed.
125,000 options at an exercise price of $0.66 create potential future share issuance but no immediate share sale.
The options expire on 09/29/2035, providing a long exercise window. As of the filing, 125,000 option-related shares are reported as directly beneficially owned following the grant. The filing does not disclose current outstanding share count or present market price, so potential dilution cannot be quantified from this document alone.